PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

PEGS Boston – 17/02/2025
NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

BioNTech buys MAB Discovery’s antibody research unit

  • German biotech BioNTech said it will buy all of MAB Discovery’s assets, employees and proprietary methods for generation of monoclonal antibodies in a deal announced Wednesday.
  • “Having exclusive access to MAB Discovery’s finely-tuned proprietary know-how dramatically expands BioNTech’s targeting ligand repertoire and enables us to directly, rapidly and efficiently produce new [monoclonal antibody] candidates,” BioNTech CEO Ugur Sahin said in a statement.
  • For its part, MAB Discovery will hold on to the rights to its preclinical development pipeline and maintain its current third-party service agreements. No financial details were disclosed.

Known for its work in the field of messenger RNA therapeutics, BioNTech is looking for new ways to grow.

Earlier this month, the private company an extension of a research collaboration with Sanofi that included an 80 million euro (or about $90 million) investment in equity from the French drugmaker.

BioNTech’s focus is on how messenger RNA can be used to spur a therapeutic response from the body, and the biotech has developed a pipeline with seven candidates in clinical testing.

Phase 1 results on one such mRNA treatment, an individualized immunotherapy for metastatic melanoma, were published in Nature in 2017.

The German company also has development or licensing deals in place with Roche’s Genentech, Sanofi, Pfizer, GenMab and Genevant.

BioNTech’s already familiar with MAB Discovery, having worked with the company for the past five years through a research collaboration. BioNTech had already begun using MAB Discovery’s technology to generate antibodies.

MAB Discovery’s technology will be used with BioNTech platforms including RiboMABS, the company stated.

Several other drugmakers are also betting heavily on the potential of mRNA to generate therapeutic antibodies, delivering the code for a protein rather than the protein itself. Moderna Therapeutics, a well-funded biotech based in Cambridge, Massachusetts, is perhaps the best known but others like Gritstone Oncology and Neon Therapeutics are also working in the field.

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40